{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:59:46Z","timestamp":1758279586499,"version":"3.38.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T00:00:00Z","timestamp":1323302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content>Objectives<\/jats:styled-content>: The Oral Rapamycin in ARgentina (ORAR) III trial is a randomized study comparing a strategy of oral rapamycin (OR) plus bare\u2010metal stent (BMS) versus a strategy of drug\u2010eluting stents (DES) in patients with de novo coronary lesions. The purpose of this study was to assess the 3 years cost\u2010effectiveness outcome of each strategy.<jats:styled-content>Background<\/jats:styled-content>: OR after BMS has been associated with reduction of target vessel revascularization (TVR) although its value in long\u2010term efficacy in comparison with DES is unknown.<jats:styled-content>Methods<\/jats:styled-content>: In three hospitals in Buenos Aires, Argentina, 200 patients were randomized to OR plus BMS (<jats:italic>n<\/jats:italic>= 100) or DES (<jats:italic>n<\/jats:italic>= 100). Primary objectives were costs and effectiveness. Cost analysis included in\u2010hospital and follow\u2010up costs. Safety was defined as the composite of death, myocardial infarction (MI), and stroke. Efficacy was defined as TVR.<jats:styled-content>Results<\/jats:styled-content>: Baseline characteristics between groups were similar. The 3\u2010year follow\u2010up rate was 99%. Cardiac mortality was 2% and 5% in OR group and DES group, respectively (<jats:italic>P<\/jats:italic>= 0.44). The composite of death, MI and stroke rate was 11% in OR group and 20% in DES group (<jats:italic>P<\/jats:italic>= 0.078). TVR rate was 14.5% in OR group and 17.6% in DES group (<jats:italic>P<\/jats:italic>= 0.50), respectively. Three year cumulative costs were significantly lower in the OR arm as compared to the DES arm (<jats:italic>P<\/jats:italic>= 0.0001) and DES strategy did not result cost\u2010effective according to the non\u2010inferiority test.<jats:styled-content>Conclusions<\/jats:styled-content>: At 3 years follow\u2010up, there were no differences in effectiveness between the two strategies, and DES strategy was not more cost\u2010effective as compared to OR plus BMS. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ccd.23352","type":"journal-article","created":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T19:28:20Z","timestamp":1321990100000},"page":"385-394","source":"Crossref","is-referenced-by-count":13,"title":["Randomized comparison of cost\u2010saving and effectiveness of oral rapamycin plus bare\u2010metal stents with drug\u2010eluting stents: Three\u2010year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial"],"prefix":"10.1002","volume":"80","author":[{"given":"Alfredo E.","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo M.","family":"Rodriguez\u2010Granillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Antoniucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Mieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Fernandez\u2010Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston A.","family":"Rodriguez\u2010Granillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Santaera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana","family":"Rubilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor F.","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of ORAR III Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012843"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035071"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032441"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61660-2"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000136821.99814.43"},{"key":"e_1_2_7_7_2","first-page":"581","article-title":"Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single\u2010Center Study (ORAR Trial)","volume":"15","author":"Rodriguez AE","year":"2003","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_8_2","first-page":"1386","article-title":"Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study","volume":"44","author":"Waksman R","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000138935.17503.35"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2004.050617"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.12.052"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.22301"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5I2A39"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5I2A40"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost\u2010Effectiveness in Health and Medicine","author":"Gold MR","year":"1996"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.10.012"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.016"},{"key":"e_1_2_7_18_2","first-page":"C39","article-title":"Identifying stent thrombosis, a critical appraisal of the Academic Research Consortium (ARC) consensus definition: A lighthouse and as a toe in the water","volume":"4","author":"Vranckx P","year":"2008","journal-title":"EuroIntervention"},{"key":"e_1_2_7_19_2","first-page":"53","article-title":"Revascularization strategies of coronary multiple vessel disease in the drug eluting stent era: One year follow\u2010up results of the ERACI III trial","volume":"2","author":"Rodriguez AE","year":"2006","journal-title":"EuroIntervention"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1215"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm297"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl357"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67221-2"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.09.086"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.08.015"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.18.1992"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.18.2001"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.04.001"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1215"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.08.067"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2010.07.017"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb07124.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00513.x"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.23352","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.23352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T10:02:29Z","timestamp":1741946549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.23352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,8]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/ccd.23352"],"URL":"https:\/\/doi.org\/10.1002\/ccd.23352","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"type":"print","value":"1522-1946"},{"type":"electronic","value":"1522-726X"}],"subject":[],"published":{"date-parts":[[2011,12,8]]}}}